Further clinical investigations are needed to assess the efficacy and safety of osimertinib in this brain tumor population, particularly in patients whose tumors express EGFR vIII rearrangements, and to identify which EGFR alterations may sensitize tumors to this BBB penetrant EGFR-TKI. This evidence concerns the gene EGFR and brain neoplasm.